Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, single arm, phase II trial in patients with ≥ 18 and <80
years with poor-prognosis (IPI ≥ 2) and newly diagnosed ABC-DLBCL.
Aim of the study is to assess the efficacy and the safety of R-CHOP in combination with
ibrutinib for 6 cycles followed by ibrutinib maintenance for 18 months in ABC-DLBCL patients
achieving at least a PR after the induction phase